LUMAKRAS
Drug
Amgen Inc.
Total Payments
$142.5M
Transactions
22,778
Doctors
6,759
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $32.7M | 923 | 269 |
| 2023 | $42.3M | 6,402 | 3,547 |
| 2022 | $21.3M | 9,829 | 4,414 |
| 2021 | $46.2M | 5,624 | 2,785 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $140.1M | 1,479 | 98.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 613 | 0.8% |
| Consulting Fee | $550,521 | 245 | 0.4% |
| Food and Beverage | $468,103 | 19,916 | 0.3% |
| Travel and Lodging | $218,710 | 490 | 0.2% |
| Royalty or License | $60,400 | 4 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $46,378 | 28 | 0.0% |
| Education | $1,168 | 3 | 0.0% |
Payments by Type
Research
$140.1M
1,479 transactions
General
$2.4M
21,299 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $54.7M | 5 |
| AMG 510 - Adv. KRAS G12C solid tumors_20190135 | Amgen Inc. | $26.5M | 3 |
| A Phase II Study of AMG 510 In Patients with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non | Amgen Inc. | $22.4M | 0 |
| CB100 Dose Comparison Study | Amgen Inc. | $7.2M | 0 |
| AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 | Amgen Inc. | $6.5M | 3 |
| P3 2L NSCLC Mono Comparator | Amgen Inc. | $3.2M | 0 |
| AMG 510_Ph3 NSCLC Monotherapy Comparator Trial | Amgen Inc. | $2.4M | 0 |
| Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | Amgen Inc. | $1.8M | 0 |
| A phase II study of induction AMG 510 mono- and combination therapy for surgically resectable stage IB-IIIB non-squamous NSCLC bearing a KRASG12C-mutation | Amgen Inc. | $1.4M | 0 |
| AMG 510 -BE Study 120 mg vs 320 mg in Healthy Subjects | Amgen Inc. | $1.3M | 0 |
| AMG 510-BE 120mg vs 240mg | Amgen Inc. | $1.2M | 0 |
| P1 BE 20 mg vs 320 mg | Amgen Inc. | $1.1M | 0 |
| Modulators of response to KRAS G12C inhibitor treatment | Amgen Inc. | $1.1M | 0 |
| P3 3L + Vectibix vs Pi choice CRC CB 300 | Amgen Inc. | $1.1M | 0 |
| P1 BE 4x240 mg vs 8x120 mg tabs | Amgen Inc. | $769,863 | 0 |
| A Phase I/II Study of AMG 510 in Combination with MVASI in Patients with Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC with Asymptomatic Brain Metastasis | Amgen Inc. | $748,345 | 0 |
| P2 1L Mono NSCLC CB 201 | Amgen Inc. | $660,359 | 0 |
| Identifying epigenetic mechanisms that underlie incomplete response to AMG 510 and combination therapies. | Amgen Inc. | $566,200 | 0 |
| AMG 510_Ph1 PK of sotorasib in subjects with hepatic impairment | Amgen Inc. | $536,748 | 0 |
| AMG 510 Ph2 First Line Monotherapy NSCLC. | Amgen Inc. | $536,375 | 0 |
Top Doctors Receiving Payments for LUMAKRAS — Page 271
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , NP | Family | Dayton, OH | $6.69 | 1 |
| , PA-C | Physician Assistant | Englewood, CO | $5.67 | 1 |
| , M.D | Internal Medicine | Houston, TX | $5.67 | 1 |
| , NP-C | Nurse Practitioner | Englewood, CO | $5.67 | 1 |
| , APRN, ACNP-BC | Acute Care | San Antonio, TX | $5.51 | 1 |
| , PA-C | Physician Assistant | Royal Oak, MI | $5.22 | 1 |
| , PA-C | Medical | Royal Oak, MI | $5.22 | 1 |
| , APRN | Nurse Practitioner | Naples, FL | $4.67 | 1 |
| Rachelle Tutterrow | Family | Indianapolis, IN | $3.69 | 1 |
| , DO | Medical Oncology | Royal Oak, MI | $3.52 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $142.5M
- Deciphera Pharmaceuticals Inc. $25,240
Product Information
- Type Drug
- Total Payments $142.5M
- Total Doctors 6,759
- Transactions 22,778
About LUMAKRAS
LUMAKRAS is a drug associated with $142.5M in payments to 6,759 healthcare providers, recorded across 22,778 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2021 to 2024. In 2024, $32.7M was paid across 923 transactions to 269 doctors.
The most common payment nature for LUMAKRAS is "Unspecified" ($140.1M, 98.3% of total).
LUMAKRAS is associated with 20 research studies, including "AMG 510 Ph1b Master Protocol 20190135" ($54.7M).